Anne Phelan has been appointed senior vice president, head of discovery research at Mission Therapeutics Ltd. She is joining the company, which is developing deubiquitylating enzymes to treat cancer and neurodegenerative diseases, from BenevolentAI, where she led drug discovery.
Dr Phelan has more than 20 years of experience in the pharmaceutical industry, including serving as chief operating officer and head of pharmacology at Pfizer Neusentis in Cambridge, UK. She received her PhD from the University of Liverpool and carried out post-doctoral training at the MRC Institute of Virology in Glasgow.
Mission Therapeutics announced the appointment on 20 March 2017.
Copyright 2017 Evernow Publishing Ltd